Ewa Wunsch

Ewa Wunsch


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
AGAnna Gudan
Anna Gudan
KKKatarzyna Kozłowska-Petriczko
Katarzyna Kozłowska-Petriczko
EWEwa Wunsch
Ewa Wunsch
TBTomasz Bodnarczuk
Tomasz Bodnarczuk
ESEwa Stachowska
Ewa Stachowska
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease associated with the pathological accumulation of lipids inside hepatocytes. Untreated NAFL can progress to non-alcoholic hepatitis (NASH), followed by fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The common denominator of the above-mentioned metabolic disorders seems to be insulin resistance, which occurs in NAFLD patients. Obesity is the greatest risk factor for lipid accumulation inside hepatocytes, but a part of the NAFLD patient population has a normal body weight according to the BMI index. Obese people with or without NAFLD have a higher incidence of small intestinal bacterial overgrowth (SIBO), and those suffering from NAFLD show increased intestinal permeability, including a more frequent presence of bacterial overgrowth in the small intestine (SIBO). The health consequences of SIBO are primarily malabsorption disorders (vitamin B12, iron, choline, fats, carbohydrates and proteins) and bile salt deconjugation. Undetected and untreated SIBO may lead to nutrient and/or energy malnutrition, thus directly impairing liver function (e.g., folic acid and choline deficiency). However, whether SIBO contributes to liver dysfunction, decreased intestinal barrier integrity, increased inflammation, endotoxemia and bacterial translocation is not yet clear. In this review, we focus on gut–liver axis and discuss critical points, novel insights and the role of nutrition, lifestyle, pre- and probiotics, medication and supplements in the therapy and prevention of both SIBO and NAFLD.

11 September 2018 in Liver International
Verified
Journal Article
Closed access
PDF file
MJMaciej K. Janik
Maciej K. Janik
EWEwa Wunsch
Ewa Wunsch
JRJoanna Raszeja‐Wyszomirska
Joanna Raszeja‐Wyszomirska
MMMaciej Moskwa
Maciej Moskwa
BKBeata Kruk
Beata Kruk
PMPiotr Milkiewicz
Piotr Milkiewicz

16 May 2022 in Liver International
Verified
Journal Article
Open access
ABAnnika Bergquist
Annika Bergquist
TWTobias J. Weismüller
Tobias J. Weismüller
CLCynthia Levy
Cynthia Levy
CRChristian Rupp
Christian Rupp
DJDeepak Joshi
Deepak Joshi
HLHenrike Lenzen
Henrike Lenzen
Background & Aims: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow‐up strategies in PSC with the hypothesis that regular imaging improves survival. Methods: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow‐up from 1 January 2000, until death or last clinical follow‐up alive. The primary endpoint was all‐cause mortality. Results: A broad variety of different follow‐up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow‐up, was 0.61 (0.47–0.80) for scheduled imaging with and without ERCP; 0.64 (0.48–0.86) for US/MRI and 0.53 (0.37–0.75) for follow‐up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high‐grade dysplasia as a time‐dependent covariate, HR 0.57 (0.44–0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow‐up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed. Conclusions: Follow‐up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.

7 November 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
EWEwa Wunsch
Ewa Wunsch
GNGary L. Norman
Gary L. Norman
MMMalgorzata Milkiewicz
Malgorzata Milkiewicz
MKMarcin Krawczyk
Marcin Krawczyk
CBChelsea Bentow
Chelsea Bentow
PMPiotr Milkiewicz
Piotr Milkiewicz
Summary: Background: Primary sclerosing cholangitis (PSC) is associated with progressive liver disease and cholangiocarcinoma. Although risk stratification is crucial for making clinical decisions, it is hindered by a scarcity of proven prognostic markers.Aims: To assess the value of novel anti‐glycoprotein 2 (anti‐GP2) and anti‐neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3‐ANCA) in combination with PSC‐specific clinical and laboratory markers as predictors of quality of life, disease severity, and cholangiocarcinoma in two large, independent cohorts of PSC patientsMethods: Discovery (338 Polish patients) and validation (178 German patients) cohorts with PSC were evaluated. Anti‐GP2 (isoforms 1/4) was detected by ELISAs and PR3‐ANCA by chemiluminescence immunoassay. Clinical and laboratory data were collected and analysed. The outcome was defined as liver transplantation‐free survival and occurrence of cholangiocarcinoma during follow‐up.Results: In the discovery group, anti‐GP21/4 IgA and PR3‐ANCA were associated with liver dysfunction, anti‐GP21/4 IgA with risk scores for PSC and anti‐GP24 IgA with cirrhosis. All cholangiocarcinoma patients were positive for PR3‐ANCA and/or anti‐GP24 IgA. The association between anti‐GP2 IgA and liver biochemistry, risk scores, cirrhosis, impaired survival, and cholangiocarcinoma was confirmed in the validation cohort. Cox proportional‐hazards regression indicated anti‐GP21 IgA as an independent variable of poor outcome in both study cohorts. Analysis of the combined data showed that anti‐GP24 IgA and PR3‐ANCA were independent predictors for cholangiocarcinoma, while anti‐GP21 IgA and PR3‐ANCA were indicators for poor survival.Conclusions: Anti‐GP2 and PR3‐ANCA are prognostic antibodies in PSC as they identify patients at risk of severe disease, poor survival and biliary cancer.

10 February 2011 in Liver International
Verified
Journal Article
Closed access
PDF file
EWEwa Wunsch
Ewa Wunsch
Barbara SzymanikBarbara Szymanik
Barbara Szymanik
MPMichal Post
Michal Post
Wojciech M. MarliczWojciech M. Marlicz
Wojciech M. Marlicz
MMMarta Mydłowska
Marta Mydłowska
PMPiotr Milkiewicz
Piotr Milkiewicz

8 May 2013 in Liver International
Verified
Journal Article
Closed access
PDF file
EWEwa Wunsch
Ewa Wunsch
DKDorota Koziarska
Dorota Koziarska
KKKatarzyna Kotarska
Katarzyna Kotarska
PNPrzemysław Nowacki
Przemysław Nowacki
PMPiotr Milkiewicz
Piotr Milkiewicz